Skip to main content

Advertisement

Table 1 Baseline characteristics of patients with mCRC according to MPV levels

From: Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study

Variables Total n (%) MPV ≥ 9.75 MPV<9.75 P value
Age (years)     0.6329
≤65 209(79.2%) 135(78.0%) 74(81.3%)  
>65 55(20.8%) 38(22.0%) 17(18.7%)  
Gender     0.9753
Male 157(59.4%) 103(59.5%) 54(59.3%)  
Female 107(40.6%) 70(40.5%) 37(40.7%)  
Location     0.5950
Colon 164 (62.3%) 106(61.3%) 59 (64.8%)  
Rectum 99 (37.7%) 67 (38.7%) 32(35.2%)  
Regimen     0.3024
Oxaliplatin 125(46.2%) 86(49.7%) 39(42.9%)  
Irinotecan 142(53.8%) 87(50.3%) 52(57.1%)  
Histology     0.3593
adenocarcinoma 239(90.5%) 161(93.1%) 78(85.7%)  
mucinous adenocarcinoma 15(5.7%) 7(4.0%) 8(8.8%)  
signet-ring cell carcinoma 4(1.5%) 2(1.2%) 2(2.2%)  
NK 6(2.3%) 3(1.7%) 3(3.3%)  
Metastasis pattern     0.4852
simultaneous 146(55.3%) 93 (53.8%) 53(58.2%)  
metachronous 118(44.7%) 80(46.2%) 38(41.7%)  
Efficacy     0.0166
CR + PR 84(31.8%) 65(37.6%) 19(20.9%)  
SD 132(50.0%) 81(46.8%) 51(56.0%)  
PD 27(10.2%) 18(10.4%) 9(9.9%)  
NK 21(8.0%) 9(5.2%) 12(13.2%)  
  1. Abbreviations: NK not known, CR complete response, SD stable disease, PD progression disease